Tinubu Square Appoints Aurelien Pelletier as Chief Product & Technology Officer
Tinubu Square, a proven SaaS solutions editor and a leader in enabling Credit Insurance & Surety digital transformation, is expanding. To sustain its current growth, Tinubu recently made acquisitions, onboarded new technologies and is equipping itself with the capabilities to achieve its ambitions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220126005498/en/
Tinubu Square - Aurelien PELLETIER - CPTO
This is reflected in the investments made in its products, but also in the evolution of its organization, such as the arrival of Aurélien Pelletier as Chief Product & Technology Officer, a recognized specialist in cutting-edge digital technology.
His role will be to accelerate Tinubu’s progression as a high-performance "software factory" and drive its products' evolution toward an end-to-end technological platform, a "Digital Highway" for our Credit Insurance & Surety customers connecting their entire ecosystem.
Tinubu’s endeavor and our new CPTO’s mission are about fostering flexibility and agility for a faster and still highly reliable technical delivery. In short, uphold our promise, "You are an insurer, and you want to focus on your field of expertise. We can bring to you the best technology to enable you do your business more efficiently."
Aurélien has more than 20 years of experience working in the tech industry providing best-in-class services, and a proven 10-year track record at C-level positions.
At the beginning of the millennium, he worked in the software design and delivery consulting services field for Atos as a technical architect working on innovation. In 2012, he joined Sfeir as CTO to advance its position into a leader on digital transformation and cloud computing projects. Then, from 2017 to 2020, he became the CTO of PrestaShop, a leading open-source e-commerce solution, where he defined and led the tech vision and strategy of the company.
With his deep experience in Agile methodologies, DevOps, continuous delivery, open sources, cloud computing and Web APIs, Aurélien is not only the perfect match for Tinubu’s objectives, but the love for his fields of expertise is also what drives him.
After having worked on all types of information system architectures, today he has developed a passion for organizational architecture – and the many bridges that exist between these two specialties.
“We are continuously working at strengthening the technological side of Tinubu’s solutions and having on board someone like Aurélien who masters the most advanced technologies and methodologies is what we were looking for. He is a great asset and resource to keep improving our ability to bring best-in-class technology to our customers through our SaaS platform,” declares Olivier Placca, Deputy CEO of Tinubu Square.
“I have known Tinubu for a long time and have a lot of trust in the executive team and its vision. I am excited by the ambitions, the potential and the international scope that define Tinubu. I think that combination is a very strong point of attraction for new talents and for those who already have experience working on a global market,” states Aurélien Pelletier.
About Tinubu Square – www.tinubu.com — @TinubuGroup
Tinubu Square is the industry-leading SaaS platform vendor, enabling Credit Insurance & Surety digital transformation. For more than 20 years, Tinubu Square has provided Credit & Surety insurers across the globe with software and services allowing them to offer best-in-class customer experience, as well as significantly reduce their exposure to risk and their financial, operational, and technical costs. Tinubu Square has an international footprint with customers in over 20 countries, including 30 of the top 60 worldwide Credit & Surety underwriters.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220126005498/en/
Contact information
Press contact
Tinubu Square: Lotta Bonde
lbe@tinubu.com
Phone: +33 1 55 95 85 85
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
